HOUSE_OVERSIGHT_026366.jpg
2.38 MB
Extraction Summary
0
People
6
Organizations
4
Locations
2
Events
0
Relationships
3
Quotes
Document Information
Type:
Corporate communication / product information sheet
File Size:
2.38 MB
Summary
This document is a corporate communication and product information sheet for the prescription drug Praluent (alirocumab), manufactured by Sanofi. It details the ODYSSEY clinical trial program, provides important safety information for patients, and includes a legal disclaimer. The document is marked with the identifier 'HOUSE_OVERSIGHT_026366' but contains no information whatsoever related to Jeffrey Epstein, his associates, finances, or travel.
Organizations (6)
| Name | Type | Context |
|---|---|---|
| Sanofi |
An integrated global healthcare company that discovers, develops, and distributes therapeutic solutions, including Pr...
|
|
| Genzyme |
Mentioned as one of Sanofi's growth platforms ('the new Genzyme').
|
|
| FDA (Food and Drug Administration) |
The U.S. agency to which negative side effects of prescription drugs should be reported via www.fda.gov/medwatch or 1...
|
|
| EURONEXT |
The Paris stock exchange where Sanofi is listed under the ticker SAN.
|
|
| NYSE (New York Stock Exchange) |
The New York stock exchange where Sanofi is listed under the ticker SNY.
|
|
| HOUSE_OVERSIGHT |
Appears as a Bates number or document identifier ('HOUSE_OVERSIGHT_026366') in the footer, suggesting the document wa...
|
Timeline (2 events)
Not specified
ODYSSEY Phase 3 program: A large-scale clinical trial program for the investigational LDL cholesterol-lowering therapy, Praluent (alirocumab), involving over 23,500 patients in 14 global trials.
Global
23,500+ patients
Ongoing (at time of writing)
ODYSSEY OUTCOMES trial: An ongoing trial to evaluate the cardiovascular benefits of Praluent in approximately 18,000 patients.
Not specified
18,000 patients
Key Quotes (3)
"The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of"Source
HOUSE_OVERSIGHT_026366.jpg
Quote #1
"Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT."Source
HOUSE_OVERSIGHT_026366.jpg
Quote #2
"HOUSE_OVERSIGHT_026366"Source
HOUSE_OVERSIGHT_026366.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document